TY - JOUR
T1 - Assessment of the soluble proteins HMGB1, CD40L and CD62P during various platelet preparation processes and the storage of platelet concentrates
T2 - The BEST collaborative study
AU - Biomedical Excellence for Safer Transfusion (BEST) Collaborative
AU - Cognasse, Fabrice
AU - Hamzeh Cognasse, Hind
AU - Eyraud, Marie Ange
AU - Prier, Amélie
AU - Arthaud, Charles Antoine
AU - Tiberghien, Pierre
AU - Begue, Stephane
AU - de Korte, Dirk
AU - Gouwerok, Eric
AU - Greinacher, Andreas
AU - Aurich, Konstanze
AU - Noorman, Femke
AU - Dumont, Larry
AU - Kelly, Kathleen
AU - Cloutier, Marc
AU - Bazin, Renée
AU - Cardigan, Rebecca
AU - Huish, Sian
AU - Smethurst, Peter
AU - Devine, Dana
AU - Schubert, Peter
AU - Johnson, Lacey
AU - Marks, Denese C
N1 - Funding Information:
This work was supported by grants from the EFS, Saint‐Denis, France, and the “Les Amis de Rémi” Association in Savigneux, France. The Australian Government funds the Australian Red Cross Lifeblood to provide blood, blood products, and services to the Australian community. We also wish to thank the Canadian Blood Services for supporting this work.
Funding Information:
The authors are grateful to the medical staff and personnel of Etablissement Français du Sang (EFS) Auvergne-Rhône-Alpes, Saint-Etienne, France, for collecting and contributing to the study data. We are also grateful to all partners for their input. The Canadian Blood Service wishes to thank the staff of the netCAD Lab for producing the components used in these studies. Héma-Québec is grateful to all the volunteer donors who participated in the study. We are also indebted to Marie-Ève Allard and Marie-Joëlle de Grandmont for their help in product collection and preparation. This work was supported by grants from the EFS, Saint-Denis, France, and the “Les Amis de Rémi” Association in Savigneux, France. The Australian Government funds the Australian Red Cross Lifeblood to provide blood, blood products, and services to the Australian community. We also wish to thank the Canadian Blood Services for supporting this work. The authors are also grateful to the blood donors of this international study (BEST#137). The authors are scientific or guest members of the Biomedical Excellence for Safer Transfusion (BEST) Collaborative, an international research organization that works collaboratively to improve transfusion-related services by standardizing analytical techniques, developing new procedures, conducting systematic reviews and carrying out clinical and laboratory studies (http://bestcollaborative.org/). The following international study centres participated in this study: Établissement Français du Sang (France): Fabrice Cognasse, Hind Hamzeh Cognasse, Marie Ange Eyraud, Amélie Prier, Charles Antoine Arthaud, Pierre Tiberghien and Stephane Begue Sanquin Blood Bank (The Netherlands): Dirk de Korte and Eric Gouwerok Institut für Immunologie und Transfusionsmedizin, Universitätsmedizin Greifswald, (Germany): Andreas Greinacher and Konstanze Aurich Military Blood Bank, Ministry of Defense, Utrecht (the Netherlands): Femke Noorman Vitalant Research Institute (USA): Larry Dumont and Kelly Kathleen Héma-Québec (Canada): Renée Bazin and Marc Cloutier NHS Blood (UK): Rebecca Cardigan, Sian Huish and Peter Smethurst Canadian Blood Services (Canada): Dana Devine and Peter Schubert Australian Red Cross Lifeblood (Australia): Denese C Marks and Lacey Johnson
Publisher Copyright:
© 2022 AABB.
PY - 2022/12/1
Y1 - 2022/12/1
N2 - BACKGROUND: Structural and biochemical changes in stored platelets are influenced by collection and processing methods. This international study investigates the effects of platelet (PLT) processing and storage conditions on HMGB1, sCD40L, and sCD62P protein levels in platelet concentrate supernatants (PCs).STUDY DESIGN/METHODS: PC supernatants (n = 3748) were collected by each international centre using identical centrifugation methods (n = 9) and tested centrally using the ELISA/Luminex platform. Apheresis versus the buffy coat (BC-PC) method, plasma storage versus PAS and RT storage versus cold (4°C) were investigated. We focused on PC preparation collecting samples during early (RT: day 1-3; cold: day 1-5) and late (RT: day 4-7; cold: day 7-10) storage time points.RESULTS: HMGB1, sCD40L, and sCD62P concentrations were similar during early storage periods, regardless of storage solution (BC-PC plasma and BC-PC PAS-E) or temperature. During storage and without PAS, sCD40L and CD62P in BC-PC supernatants increased significantly (+33% and +41%, respectively) depending on storage temperature (22 vs. 4°C). However, without PAS-E, levels decreased significantly (-31% and -20%, respectively), depending on storage temperature (22 vs. 4°C). Contrastingly, the processing method appeared to have greater impact on HMGB1 release versus storage duration. These data highlight increases in these parameters during storage and differences between preparation methods and storage temperatures.CONCLUSIONS: The HMGB1 release mechanism/intracellular pathways appear to differ from sCD62P and sCD40L. The extent to which these differences affect patient outcomes, particularly post-transfusion platelet increment and adverse events, warrants further investigation in clinical trials with various therapeutic indications.
AB - BACKGROUND: Structural and biochemical changes in stored platelets are influenced by collection and processing methods. This international study investigates the effects of platelet (PLT) processing and storage conditions on HMGB1, sCD40L, and sCD62P protein levels in platelet concentrate supernatants (PCs).STUDY DESIGN/METHODS: PC supernatants (n = 3748) were collected by each international centre using identical centrifugation methods (n = 9) and tested centrally using the ELISA/Luminex platform. Apheresis versus the buffy coat (BC-PC) method, plasma storage versus PAS and RT storage versus cold (4°C) were investigated. We focused on PC preparation collecting samples during early (RT: day 1-3; cold: day 1-5) and late (RT: day 4-7; cold: day 7-10) storage time points.RESULTS: HMGB1, sCD40L, and sCD62P concentrations were similar during early storage periods, regardless of storage solution (BC-PC plasma and BC-PC PAS-E) or temperature. During storage and without PAS, sCD40L and CD62P in BC-PC supernatants increased significantly (+33% and +41%, respectively) depending on storage temperature (22 vs. 4°C). However, without PAS-E, levels decreased significantly (-31% and -20%, respectively), depending on storage temperature (22 vs. 4°C). Contrastingly, the processing method appeared to have greater impact on HMGB1 release versus storage duration. These data highlight increases in these parameters during storage and differences between preparation methods and storage temperatures.CONCLUSIONS: The HMGB1 release mechanism/intracellular pathways appear to differ from sCD62P and sCD40L. The extent to which these differences affect patient outcomes, particularly post-transfusion platelet increment and adverse events, warrants further investigation in clinical trials with various therapeutic indications.
KW - inflammation
KW - platelets
KW - storage lesion
KW - transfusion
UR - https://www.scopus.com/pages/publications/85143490637
U2 - 10.1111/trf.17200
DO - 10.1111/trf.17200
M3 - Article
SN - 0041-1132
JO - Transfusion
JF - Transfusion
ER -